ARTICLE : Celgene Wins Chinese Approval for Revlimid ( CELG ) link
ARTICLE : Celgene Wins Chinese Approval for Revlimid
By Dan Carroll | More Articles | Save For Later
February 13, 2013 | Comments (0)
Biotech company Celgene (NASDAQ: CELG ) has announced that its subsidiary Celgene International Sàrl has won full regulatory approval from the China State Food and Drug Administration for Revlimid.
Revlimid, used to treat relapsed or refractory multiple myeloma in patients who have already undergone at least one therapy, is expected to be available to Chinese patients sometime late in the second quarter. The drug, which is already approved in numerous other locations, recorded more than $3.7 billion in sales in 2012.